Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

China Pharma Holdings’ Growth Moderates in Q2

publication date: Aug 6, 2008

China Pharma Holdings, Inc. (OTCBB: CPHI) reported that its Q2 revenues climbed 32% to $11.3 million. Net income was up by 21% at $4 million. While these numbers are moving in the right direction, the Q2 results are less impressive than the 60% revenue growth and 78% profit increase of Q1. China Pharma makes and markets generic and branded biopharmaceuticals in China. More details...

Stock Symbol: (OTCBB: CPHI)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital